Pembrolizumab
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Explore 6 assets in Subcutaneous Panniculitis-Like T-Cell Lymphoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04795869CT.gov Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT03598998CT.gov Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Subcutaneous Panniculitis-Like T-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Northwestern University | P2 | B · 60 |
| Prednisone | Shandong Provincial Hospital | P4 | BBB |
| Etoposide | Shandong Provincial Hospital | P4 | BBB |
| (+)-Vincristine | Shandong Provincial Hospital | P4 | BBB |
| Isocyclophosphamide | Shandong Provincial Hospital | P4 | BB |
| Adriamycin | Ruijin Hospital | P4 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BB |
| Theprubicin | Ruijin Hospital | P4 | BB |
| Methotrexate | Ruijin Hospital | P4 | B |
+7 more in the Subcutaneous Panniculitis-Like T-Cell Lymphoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Subcutaneous Panniculitis-Like T-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-subcutaneous-panniculitis-like-t-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →